-
EHA 2026 Highlight: Prof. Lars Bullinger Deciphers 25 Years of Molecular Hematology Evolution—From Gene Expression Profiles to Precision Diagnosis and Treatment Profiles
In the Presidential Session of the 2026 European Hematology Association (EHA) Annual Meeting, Prof. Lars Bullinger from Charité – Universitätsmedizin Berlin delivered a keynote speech titled “From gene profiles to therapy profiles – a quarter century of molecular hematology.” Combining his personal research experience with global major scientific breakthroughs, Prof. Bullinger provided a profound analysis…
-
Second-generation vs. First-generation FLT3 Inhibitors: PASHA Study Reveals Clinical Benefits and Challenges of Gilteritinib Combined with First-line Intensive Chemotherapy
In the treatment of acute myeloid leukemia (AML), the FLT3 mutation is one of the most common genetic abnormalities (accounting for approximately 30%), and the evolution of its treatment strategies has always been a focus of clinical attention. Although the first-generation FLT3 inhibitor midostaurin and the second-generation inhibitor quizartinib have been approved for first-line treatment,…
-
83% EFS Reaches New High! AIEOP-BFM Study Confirms Replacing Chemotherapy with Blinatumomab Significantly Improves Prognosis in High-Risk B-ALL Pediatric Patients
At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Martin Schrappe, on behalf of the AIEOP-BFM consortium, announced the latest analysis data from the Phase III randomized controlled clinical trial AIEOP-BFM ALL 2017. This study aimed to explore the clinical benefits of using the bispecific antibody Blinatumomab to completely replace two cycles of high-intensity…
-
As of the data analysis date, a total of 17 patients were enrolled. The median age was 63 years, the median number of prior treatment lines was 4, and 65% of patients had received at least one prior allogeneic hematopoietic stem cell transplant.
Although progress has been made in the treatment of Acute Myeloid Leukemia (AML) over the past few decades, clinical options remain very limited for patients with relapsed/refractory (R/R) disease. Chimeric Antigen Receptor T-cell (CAR-T) therapy has achieved revolutionary breakthroughs in B-cell malignancies; however, its application in the field of AML has faced significant challenges due…
-
Precision Subtyping and BTKi Upfront: Professor Mats Jerkeman Details MCL Guideline Updates and Clinical Pathway Optimization
In the recent European Hematology Association (EHA) Annual Meeting, Professor Mats Jerkeman from Lund University, Sweden, provided an in-depth interpretation of the diagnosis and latest treatment guidelines for Mantle Cell Lymphoma (MCL). With the release of results from several large-scale clinical trials (such as TRIANGLE, ECHO, SHINE, etc.), the treatment landscape for MCL is undergoing…
-
New Breakthrough in Fixed-Duration Regimens: PVR Regimen Reduces Risk of Progression by 45% Compared to VR in R/R CLL Patients
At a recent international academic conference, Professor Matthew Davids from the Dana-Farber Cancer Institute in the United States announced the interim analysis results of the Phase 3 randomized controlled clinical trial, BRUIN CLL-322. This study aimed to evaluate the efficacy and safety of fixed-duration pirtobrutinib plus venetoclax and rituximab (PVR regimen) versus venetoclax plus rituximab…
-
52% Reduction in Risk of Progression! Phase III SUCCESSOR-2 Trial Confirms Superior Efficacy of MeziKd in RRMM Patients
At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Meletios Dimopoulos from the National and Kapodistrian University of Athens was invited to deliver a presentation titled “Mezigdomide, Carfilzomib, and Dexamethasone (MeziKd) vs Carfilzomib and Dexamethasone (Kd) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 SUCCESSOR-2 Trial.”
-
Deep Remission and Long-term Benefit: MAJESTEC-4 Study Reveals the Remarkable Potential of Teclistamab ± Lenalidomide as Post-transplant Maintenance Therapy for NDMM
At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Niels van de Donk from the Amsterdam University Medical Center (Amsterdam UMC), representing the EMN30 study group, announced the updated safety run-in (SRI) results of the EMN30/MAJESTEC-4 study. This study aims to evaluate the safety and preliminary efficacy of the BCMA×CD3 bispecific antibody Teclistamab (Tec),…
Connecting Medical Expertise through Media